Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Avibactam/ceftazidime - Allergan/Pfizer

Drug Profile

Avibactam/ceftazidime - Allergan/Pfizer

Alternative Names: AVE 1330/ceftazidime; AVE 1330A/ceftazidime; Avibactam/ceftazidime pentahydrate; AVYCAZ; CAZ 104; CAZ-AVI; Ceftazidime pentahydrate/avibactam; Ceftazidime/AVE 1330; Ceftazidime/AVE 1330A; Ceftazidime/NXL 104; NXL 104/ceftazidime; Zavicefta

Latest Information Update: 18 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novexel
  • Developer Allergan; AstraZeneca; Cerexa; Novexel; Pfizer
  • Class Amides; Antibacterials; Cephalosporins; Heterocyclic bicyclo compounds; Small molecules; Sulfates
  • Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Gram-negative infections; Intra-abdominal infections; Nosocomial pneumonia; Urinary tract infections

Most Recent Events

  • 17 Oct 2019 Pfizer and Allergan plans a phase II trial for Gram-negative infections (In infants; In neonates) in USA, in March 2020 (IV) (NCT04126031) (EudraCT2018-002800-16)
  • 06 Aug 2019 Pfizer plans a phase I trial for Nosocomial pneumonia (In children, In infants) in USA in November 2019 (NCT04040621)
  • 18 Mar 2019 Preregistration for Intra-abdominal infections (Combination therapy, In adolescents, In children, In infants, Complicated) in USA (IV) before 18 March 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top